BioWorld

Nov. 3, 2008

Biogen Idec Joins Genentech, Roche on Anti-CD20 Antibody

Biogen Idec Inc. said it will pay a $31.5 million up-front fee to join Genentech Inc. and F. Hoffmann-La Roche Ltd. in the development of a humanized anti-CD20 monoclonal antibody, GA101. (BioWorld Today) Read More

Polyphor Would Get $7M Boost in Eye Drug Deal with Allergan

How Biotech Can Make Even Cash Look Bad

Panel: Focus on Long Term to Weather Economic Storm

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...